- Ezemba C. C.1, Godson-Ahuaza C.V.2, Okeke C.O.3, Shittu T.H.4, Obiasogu S. P.5, Adeyemo A.S.6, Johnson U.E.7, Victor O.E.8
- 1ChyChy Gilgal Laboratory and Consultancy services, 2University of Nigeria Nsukka , 3University of Benin, 4Olabisi Onabanjo University, 5COOU ULI, 6Federal University of Technology, Akure, 7University of Port Harcourt, 8Chukwuemeka Odumegwu Ojukwu University
Cancer vaccines are a novel approach in the fight against cancer, aiming to stimulate the immune system to recognize and destroy tumour cells. This review explores the primary mechanisms by which cancer vaccines induce immune responses, the role of antigen presentation, dendritic cell activation, and T-cell-mediated tumour destruction. While many vaccines have demonstrated success in clinical trials for cancers such as melanoma, prostate, and lung cancers, issues related to antigen selection, delivery systems, and vaccine-induced side effects remain. To address these challenges, we assessed the safety and efficacy of current cancer vaccines, using clinical trial data to highlight both successes and limitations. Emerging trends, such as neoantigen-based vaccines and mRNA platforms, offer novel solutions through personalized treatments that target patient-specific tumour mutations to enhance vaccine potency. Personalized vaccines and combination therapies represent pathways to overcoming current limitations, offering hope for more effective, durable, and patient-specific cancer treatments. Finding the right balance between future research directions and the challenges we face will be essential for overcoming immune resistance and fully advancing this promising field.
